804TiP CaboPoint: A phase II study of second-line cabozantinib in patients with metastatic renal cell carcinoma (RCC)

por Albiges, L., Schmidinger, M., Taguieva-Pioger, N., Perol, D., Gruenwald, V.
Publicado 2020

Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinoma

por Saroufim, A, Messai, Y, Hasmim, M, Rioux, N, Iacovelli, R, Verhoest, G, Bensalah, K, Patard, J-J, Albiges, L, Azzarone, B, Escudier, B, Chouaib, S
Publicado 2014

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

por Tomita, Y., Motzer, R.J., Choueiri, T.K., Rini, B.I., Miyake, H., Uemura, H., Albiges, L., Fujii, Y., Umeyama, Y., Wang, J., Mariani, M., Schmidinger, M.
Publicado 2022

Bamlanivimab + etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies

por Pommeret, F., Colomba, J., Bigenwald, C., Laparra, A., Bockel, S., Bayle, A., Michot, J.-M., Hueso, T., Albiges, L., Tiberghien, P., Marot, S., Jary, A., Lacombe, K., Barlesi, F., Griscelli, F., Colomba, E.
Publicado 2021

Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone

por Massard, C., Mateo, J., Loriot, Y., Pezaro, C., Albiges, L., Mehra, N., Varga, A., Bianchini, D., Ryan, C. J., Petrylak, D. P., Attard, G., Shen, L., Fizazi, K., de Bono, J.
Publicado 2017

Tocilizumab, an anti-IL-6 receptor antibody, to treat COVID-19-related respiratory failure: a case report

por Michot, J.-M., Albiges, L., Chaput, N., Saada, V., Pommeret, F., Griscelli, F., Balleyguier, C., Besse, B., Marabelle, A., Netzer, F., Merad, M., Robert, C., Barlesi, F., Gachot, B., Stoclin, A.
Publicado 2020

Online public interest in urological cancers during the Covid-19 pandemic: What can “Dr. Google” teach us?

por Khene, Z-E., Guérin, S., Khene, F., Pradère, B., Roumiguié, M., Mathieu, R., Albiges, L., Borchiellini, D., Pignot, G., Neuzillet, Y., Ploussard, G., Bigot, P., De La Taille, A., Rouprêt, M., Bensalah, K.
Publicado 2022

1688P Outcome of older cancer patients infected with COVID-19 at Gustave Roussy Cancer Center

por Hauchecorne, M., Baldini, C., Foulon, S., Bayle, A., Gachot, B., Pommeret, F., Willekens, C., Griscelli, F., Netzer, F., Balleyguier, C., Ammari, S., André, F., Scotté, F., Besse, B., Soria, J-C., Barlesi, F., Albiges, L.
Publicado 2020

Association of cabozantinib pharmacokinetics, progression and toxicity in metastatic renal cell carcinoma patients: results from a pharmacokinetics/pharmacodynamics study

por Cerbone, L., Combarel, D., Geraud, A., Auclin, E., Foulon, S., Alves Costa Silva, C., Colomba, E., Carril, L., Derosa, L., Flippot, R., Mir, O., Khoudour, N., Blanchet, B., Escudier, B., Paci, A., Albiges, L.
Publicado 2021

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium ris...

por Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.
Publicado 2023

Severe COVID-19 in patients with hematological cancers presenting with viremia

por Michot, J.M., Hueso, T., Ibrahimi, N., Pommeret, F., Willekens, C., Colomba, E., Francis, S., Bayle, A., Cournède, P.H., Merad, M., Foulon, S., Albiges, L., Gachot, B., Barlesi, F., Soria, J.C., Ribrag, V., Griscelli, F.
Publicado 2021

Vinflunine–gemcitabine versus vinflunine–carboplatin as first-line chemotherapy in cisplatin-unfit patients with advanced urothelial carcinoma: results of an international randomiz...

por De Santis, M., Wiechno, P. J., Bellmunt, J., Lucas, C., Su, W.-C., Albiges, L., Lin, C.-C., Senkus-Konefka, E., Flechon, A., Mourey, L., Necchi, A., Loidl, W. C., Retz, M. M., Vaissière, N., Culine, S.
Publicado 2016

RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs

por Beuselinck, B, Jean-Baptiste, J, Couchy, G, Job, S, De Reynies, A, Wolter, P, Théodore, C, Gravis, G, Rousseau, B, Albiges, L, Joniau, S, Verkarre, V, Lerut, E, Patard, J J, Schöffski, P, Méjean, A, Elaidi, R, Oudard, S, Zucman-Rossi, J
Publicado 2015

1639P Impact of COVID-19 on ongoing oncological and hematological treatment strategy

por Bayle, A., Ouali, K., Colomba, E., Ibrahimi, N., Foulon, S., Gachot, B., Willekens, C., Stoclin, A., Merad, M., Griscelli, F., Sun, R., Ammari, S., Michot, J-M., André, F., Scotté, F., Besse, B., Soria, J-C., Barlesi, F., Albiges, L., Pommeret, F.
Publicado 2021

1617P Sustained cancer clinical trial activity during the COVID-19 pandemic

por Bayle, A., Baldini, C., Romano, P. Martin, Michot, J-M., Champiat, S., Bahleda, R., Gazzah, A., Marabelle, A., Verlingue, L., Geraud, A., Morel, D., Michiels, S., Ribrag, V., Hollebecque, A., Albiges, L., Besse, B., Soria, J-C., Massard, C., Barlesi, F., Postel-Vinay, S.
Publicado 2021

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial

por Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.
Publicado 2021

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ES...

por Choueiri, T.K., Larkin, J., Pal, S., Motzer, R.J., Rini, B.I., Venugopal, B., Alekseev, B., Miyake, H., Gravis, G., Bilen, M.A., Hariharan, S., Chudnovsky, A., Ching, K.A., Mu, X.J., Mariani, M., Robbins, P.B., Huang, B., di Pietro, A., Albiges, L.
Publicado 2021

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

por Choueiri, T. K., Motzer, R. J., Rini, B. I., Haanen, J., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Gravis-Mescam, G., Uemura, M., Lee, J. L., Grimm, M.-O., Gurney, H., Schmidinger, M., Larkin, J., Atkins, M. B., Pal, S. K., Wang, J., Mariani, M., Krishnaswami, S., Cislo, P., Chudnovsky, A., Fowst, C., Huang, B., di Pietro, A., Albiges, L.
Publicado 2020